ArticleBMC ophthalmology2026
Application of subretinal injection of balanced salt solution for the management of large-diameter macular holes.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy and safety of subretinal injection of balanced salt solution (BSS) combined with vitrectomy and internal limiting membrane (ILM) peeling for managing large-diameter macular holes (MHs ≥ 400 μm).
methodsA prospective interventional study was conducted on 31 eyes of 31 patients with full-thickness MHs (including 5 refractory MHs). Patients underwent 25 G vitrectomy, ILM peeling, followed by subretinal BSS injection using a 41 G needle. Outcomes were assessed at 1 and 3 months postoperatively with optical coherence tomography (OCT), best corrected visual acuity (BCVA), and microperimetry. Metrics of the microperimetry included macular integrity index (MII) and macular threshold (MT). Ten eyes completed 6 month followup. Changes in BCVA (LogMAR), MII, and MT before and after surgery, as well as MH closure and complications were compared and analyzed. Functional outcomes were analyzed only in eyes with successful type I closure.
resultsAt 1 month, 93.54% (29/31) achieved complete MH closure. BCVA improved from 1.34 ± 0.59 preoperatively to 0.67 ± 0.20 at 1 month and 0.48 ± 0.36 at 3 months (p < 0.001). MII improved from 98.77 ± 4.83 to 96.23 ± 11.38 (p = 0.015) and MT from 17.53 ± 5.04 to 22.54 ± 3.91 dB (p < 0.001) at 3 months. In 10 eyes with 6 month followup, BCVA further improved to 0.41 ± 0.30 and MT to 24.64 ± 2.35 dB (bothp < 0.05). The refractory subgroup (n = 5) achieved 100% complete closure. No complications were observed during the follow-up time.
conclusionCombined 41 G subretinal BSS injection with PPV and ILM peeling is effective and safe for treating largediameter MHs (≥400 μm), achieving high anatomical closure rates and sustained visual functional improvement up to 6 months. Preliminary outcomes in refractory MHs are favorable; larger cohorts are needed for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.